[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584843":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":38,"sex":42,"minAge":7,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Giuseppe Sanguineti, Doctor","IRCCS National Cancer Institute","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+39-06 52663010","giuseppe.sanguineti@ifo.it",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"IRCSS Regina Elena","RECRUITING","Roma","00144","Italy","IT",{"type":27,"coordinates":28},"Point",[29,30],11.10642,44.99364,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":7,"phoneExt":7,"email":17},"Giuseppe Sanguineti, Head Physician",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100584843",false,"NCT06894628","Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation","Inclusion Criteria:\n\n* patients enrolled at IRE under the \"esSBRT\" protocol (meeting the criteria of the same);\n* patients who express written informed consent personally or through their legal representative\u002Fwitness\u002Fcurator\u002Fguardian\u002Fsupport administrator (participation in the ancillary study and data processing)\n\nExclusion Criteria:\n\n* all exclusion criteria adopted for the \"esSBRT\" study.","MALE",{"count":44,"type":45},103,"ESTIMATED","OBSERVATIONAL","The study aims to validate the Decipher® genomic test, in which patients with biochemical recurrence after radical prostatectomy are treated with salvage radiotherapy with extreme hypofractionation (5+ Gy\u002Ffraction).\n\nValidating the Decipher® genomic classifier based on the expression of 22 RNA genes in the prospective study \"esSBRT\"",[49],"Prostatic Neoplasms","2025-03-18",{"date":52,"type":53},"2025-03-25","ACTUAL",{"date":55,"type":53},"2024-11-04",{"date":57,"type":45},"2027-11-04",{"name":5,"class":6},1]